Smith & Nephew PLC (SNN)

34.75
NYSE : Health Care
Prev Close 34.75
Day Low/High 0.00 / 0.00
52 Wk Low/High 26.96 / 35.82
Avg Volume 462.70K
Exchange NYSE
Shares Outstanding 451.86M
Market Cap 15.90B
EPS 1.80
P/E Ratio 28.60
Div & Yield 0.74 (2.10%)

Latest News

European Stocks Rise but London Blue Chips Slip on Stronger Pound

European Stocks Rise but London Blue Chips Slip on Stronger Pound

The FTSE 100 lagged its counterparts on Thursday following a run of broker downgrades and after a stronger pound ate into FX gains for London's blue chips.

Take Advantage of U.K. Budget to Bag Some Bargains

Take Advantage of U.K. Budget to Bag Some Bargains

Investors should look at cheap, inflation-proof stocks, which could be very cheap.

10 Safe Dividend Stocks for Protection Against Fed Rate Hikes

10 Safe Dividend Stocks for Protection Against Fed Rate Hikes

When interest rates rise, these quality dividend growth stocks should weather the storm.

Smith & Nephew Reinforces Strong Educational Commitment To Advanced Wound Management At World Union Of Wound Healing Societies Meeting (WUWHS)

Smith & Nephew Reinforces Strong Educational Commitment To Advanced Wound Management At World Union Of Wound Healing Societies Meeting (WUWHS)

Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, highlights three scientific symposia at World Union of Wound Health Societies (WUWHS) on 25-29 September 2016 in Florence, Italy.

Perrenial Target and Acquirer NuVasive Names New President and COO

Perrenial Target and Acquirer NuVasive Names New President and COO

The medical device company taps Jason Hannon, an 11-year company veteran, as its new president and COO, succeeding Patrick Miles, who was appointed vice chairman.

New Protocol Including The Use Of ALLEVYN™ LIFE Reduces Hospital-acquired Pressure Ulcers By 69% In Large Facility

New Protocol Including The Use Of ALLEVYN™ LIFE Reduces Hospital-acquired Pressure Ulcers By 69% In Large Facility

Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, announces the publication of a new research paper showing how a comprehensive ulcer prevention programme which included the use of...

Zimmer's LDR Deal Could Force Others to Grow a Dealmaking Spine

Zimmer's LDR Deal Could Force Others to Grow a Dealmaking Spine

The $1 billion transaction could inspire other medical device companies and private equity firms to bend over backwards for spinal device assets.

Rival Offer for LDR Is Unlikely, but Never Say Never

Rival Offer for LDR Is Unlikely, but Never Say Never

The hefty premium Zimmer Biomet is paying in the $1 billion deal for the spine company suggests the target's management followed a competitive process.

Medtronic Strikes Deals in Gynecology, Robotics

Medtronic Strikes Deals in Gynecology, Robotics

The medical device company is spending $350 million for the gynecology business of Smith & Nephew, and has agreed to invest in an Israeli spinal robotics company.

Government Probes for Valeant; New Board Members Put Forth

Government Probes for Valeant; New Board Members Put Forth

The embattled pharmaceutical company's move to bring in additional directors and file an overdue financial report did little to appease the markets.

Stryker Strikes Again, Buying Physio-Control

Stryker Strikes Again, Buying Physio-Control

Medical device company Stryker is paying $1.2 billion cash for defibrillator maker Physio-Control on the heels of spending $2.8 billion on disposable health care devices manufacturer Sage Products.